Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Multiple Myeloma · Renal Cell Cancer · CRVS

Corvus Pharmaceuticals

Corvus Pharmaceuticals patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Burlingame, USA HQ
2014 Founded
48 Employees
Public company Type
CRVS · NYSE Ticker
Company details
Status
Public
HQ
Burlingame, USA
Founded
2014
Employees
48
Programs
9
Drugs
4
Patents
14
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Corvus Pharmaceuticals patents

14 pharmaceutical patents indexed for Corvus Pharmaceuticals. 0 expire within 24 months.

Corvus Pharmaceuticals has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

14 patents

Patent portfolio

  1. US 12351644

    Anti-CD73 antibodies

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12023337

    Methods of treating cancer

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11897874

    Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11859007

    Humanized anti-CD73 antibodies

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11266649

    Pharmaceutical formulations

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11254686

    Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11040040

    Methods of treating cancer

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11008314

    Compounds and methods for modulating interleukin-2-inducible t-cell kinase

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10912776

    Methods of treating cancer

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10870652

    Compounds and methods for modulating bruton's tyrosine kinase

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10822426

    Humanized anti-CD73 antibodies

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10793636

    Anti-CD73 antibodies

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Corvus Pharmaceuticals have?

14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Corvus Pharmaceuticals patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.